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Abstract
Background: A large number of studies have shown an association between inherited thrombophilia and recurrent
miscarriage. It has been hypothesized that anticoagulant therapy might reduce the number of miscarriages and
stillbirth in these women. In the absence of randomized controlled trials evaluating the efficacy of anticoagulant
therapy in women with inherited thrombophilia and recurrent miscarriage, a randomized trial with adequate power
that addresses this question is needed. The objective of the ALIFE2 study is therefore to evaluate the efficacy of
low-molecular-weight heparin (LMWH) in women with inherited thrombophilia and recurrent miscarriage, with live
birth as the primary outcome.
Methods/Design: Randomized study of LMWH plus standard pregnancy surveillance versus standard pregnancy
surveillance alone.
Study population: pregnant women of less than 7 weeks’ gestation, and confirmed inherited thrombophilia with a
history of 2 or more miscarriages or intra-uterine fetal deaths, or both.
Setting: multi-center study in centers from the Dutch Consortium of Fertility studies; centers outside the
Netherlands are currently preparing to participate.
Intervention: LMWH enoxaparin 40 mg subcutaneously once daily started prior to 7 weeks gestational age plus
standard pregnancy surveillance or standard pregnancy surveillance alone.
Main study parameters/endpoints: the primary efficacy outcome is live birth. Secondary efficacy outcomes include
adverse pregnancy outcomes, such as miscarriage, pre-eclampsia, syndrome of hemolysis, elevated liver enzymes
and low platelets (HELLP syndrome), fetal growth restriction, placental abruption, premature delivery and congenital
malformations.
Safety outcomes include bleeding episodes, thrombocytopenia and skin reactions.
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Discussion: After an initial period of slow recruitment, the recruitment rate for the study has increased. Improved
awareness of the study and acknowledgement of the need for evidence are thought to be contributing to the
improved recruitment rates. We aim to increase the number of recruiting centers in order to increase enrollment
into the ALIFE2 study.
The study website can be accessed via www.ALIFE2study.org.
Trial registration: The ALIFE2 study was registered on 19 March 2012 under registration number NTR3361
Keywords: Recurrent miscarriage, Pregnancy complications, Fetal death, Thrombophilia, Anticoagulants, Aspirin,
Low-molecular-weight-heparin
Background
In all clinically recognized pregnancies, a single spontan-
eous miscarriage occurs in 14 to 19% of patients, and 1 to
5% of women experience 2 or more miscarriages (recur-
rent miscarriage) [1,2]. After comprehensive investigation,
a risk factor for recurrent miscarriage is identified in less
than half of couples [3]. Many studies have confirmed a
relationship between inherited thrombophilia and miscar-
riage and other adverse pregnancy outcomes [4,5]. The
role of thrombophilia in recurrent miscarriage can be ex-
plained partially by the concept of thrombosis of the (mi-
crovasculature of the) placenta, and partially through
inhibition of extra-villous trophoblast differentiation [6].
Therefore, anticoagulants are considered a possible ther-
apy for women with recurrent miscarriage and inherited
thrombophilia. In a recent Cochrane systematic review
and meta-analysis we reviewed the trial evidence on the
effects of antithrombotic therapy and showed that no firm
trial data are available for these women [7].
Previously, we performed a randomized, placebo con-
trolled study (ALIFE study), investigating whether as-
pirin combined with low-molecular-weight heparin
(LMWH) or aspirin alone as compared with placebo
would improve the live birth rate among 364 women
with unexplained recurrent miscarriage (<20 weeks’ ges-
tation) [8]. We found that neither aspirin combined with
nadroparin (relative risk (RR) for live birth 0.96, 95%
confidence interval (CI) 0.76 to 1.19) nor aspirin alone
(RR for live birth 0.89, 95% CI 0.71 to 1.13) improved
the chance of a live birth in women with a history of un-
explained recurrent miscarriage. In addition, no statisti-
cally significant benefits were found for women with
inherited thrombophilia, although the study was not
powered to assess this effect. The SPIN-study, another
randomized controlled trial, assessed whether enoxa-
parin and aspirin reduced the rate of miscarriage com-
pared to intensive pregnancy surveillance alone in 294
women with a history of 2 or more consecutive previous
miscarriages (<24 weeks’ gestation) [9]. Results showed
22% miscarriage in participants receiving enoxaparin
and aspirin, compared with 20% miscarriage in subjects
receiving intensive surveillance alone (odds ratio 0.91,
95% confidence interval 0.52 to 1.59). The Habenox
study also found no beneficial effect of LMWH (with as-
pirin or placebo) compared to aspirin in women with or
without thrombophilia and recurrent miscarriage [10].
Neither individually, nor combined in meta-analysis, was
any of these studies sufficiently powered to demonstrate
an effect of pharmacological therapy in the subgroup of
women with inherited thrombophilia [7]. For women
with the antiphospholipid syndrome (APS), the use of
heparin or LMWH combined with low-dose aspirin is
an effective treatment for recurrent miscarriage, [11-13]
although not demonstrated in all performed trials [14,15].
For inherited forms of thrombophilia, this effect has not
profoundly been studied yet. Very recently, results of the
TIPPS study showed that dalteparin did not reduce the in-
cidence of a composite outcome (severe or early-onset
pre-eclampsia, small-for-gestational-age infant, pregnancy
loss, or venous thromboembolism (VTE)) in pregnant
women with thrombophilia at increased risk of VTE or
with previous placenta-mediated pregnancy complications
[16]. However, again in this study, the subgroup of women
with recurrent miscarriage and inherited thrombophilia
was too small to draw conclusions of a potential effect on
the outcome live birth.
The association between inherited thrombophilia and
recurrent miscarriage together with the potential benefi-
cial effects of anticoagulant therapy in women with ac-
quired thrombophilia and recurrent miscarriage have led
some physicians to prescribe LMWH to women with re-
current miscarriage and inherited thrombophilia. While
this practice may be supported by a plausible hypothesis, a
beneficial effect of LMWH in these women still needs to
be demonstrated. Gynecologists and hematologists, who
expressed their support in the design phase of the study,
and who are currently contributing to recruitment,
recognize the urgent need for a trial such as ALIFE2
internationally.
The results of the ALIFE2 study will clarify the need
to screen for inherited thrombophilia in women with re-
current miscarriage. Current guidelines advise differently
on whether or not to test for inherited thrombophilia in
these women [17-22]. The efficacy of LMWH in women
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with recurrent miscarriage and inherited thrombophilia
has never been tested in a randomized controlled trial.
Thus, if the results of the ALIFE2 study show that
LMWH increases live birth in women with recurrent
miscarriage and inherited thrombophilia, screening for
inherited thrombophilia in this setting may be justified.
Conversely, if no evidence of a benefit is found, the use
of LMWH will not be justified and screening for inher-
ited thrombophilia will not be indicated. This will de-
crease costs of inappropriate screening, and reduce the
burden of anticoagulant treatment in pregnant women.
Methods/Design
Design of the study
The primary objective of this study is to evaluate the ef-
ficacy of LMWH in women with inherited thrombophi-
lia and recurrent miscarriage and/or intra-uterine fetal
death (≥2). The primary outcome is live birth.
Secondary objectives included efficacy and safety
objectives:
Efficacy
 To evaluate other possible effects of LMWH on
adverse pregnancy outcome other than miscarriage
(e.g., preeclampsia, intra-uterine growth restriction,
HELLP syndrome (syndrome of hemolysis, elevated
liver enzymes and low platelets) placental abruption,
premature delivery, congenital malformations, VTE)
Safety
 To evaluate the safety of LMWH in women with
recurrent miscarriage with inherited thrombophilia
by recording complications such as bleeding,
thrombocytopenia and (allergic) skin reactions
All pre-specified outcomes are listed in Table 1. Cri-
teria for the classification of bleeding are listed in
Table 2.
Other study variables include concomitant use of an-
tithrombotic drugs (such as aspirin or non-steroidal
anti-inflammatory drugs (NSAIDs), maternal age, mul-
tiple gestation, number of preceding miscarriages, ma-
ternal ethnicity, partner’s ethnicity, maternal weight,
height, and body mass index, past obstetric history,
medication, smoking, alcohol consumption, allergies,
family history of VTE and of miscarriage and/or intra-
uterine fetal death.
The study is designed as a multi-center randomized
intervention study (Figure 1). Pregnant women with a
history of recurrent miscarriage (two or more miscar-
riages or intra-uterine fetal deaths, not necessarily con-
secutive), and confirmed inherited thrombophilia are
randomized to one of two groups. Women in the
Table 1 Outcomes
Primary efficacy
outcome
Live birth (defined as birth of a living child)
Principal safety
outcome
Clinically relevant bleeding (that is major bleeding
and clinically relevant non-major bleeding)
Secondary study
outcomes
Efficacy Ongoing pregnancy beyond 12 weeks’ gestation
Preeclampsiaab
HELLP syndromeac
Intrauterine growth restrictionad
Placental abruptionae
Premature birthaf
Intra-uterine fetal deatha
Major congenital anomaliesag
Composite of confirmed deep vein thrombosis
and confirmed pulmonary embolismh
Safety Post-partum bleeding and severe post-partum
bleeding
Major bleeding
Clinically relevant non-major bleeding
Minor bleeding, including increased tendency
to bruising not fulfilling the criteria for clinically
relevant non-major bleeding
Heparin-induced thrombocytopenia
(defined according to ACCP criteria [24])
Allergic reactions (redness or itching) localized
at the injection site of LMWH
Type 1 allergy: e.g. generalized symptoms
including anaphylaxis
aDenominator for these outcomes is ongoing pregnancies beyond 12
weeks’ gestation.
bPreeclampsia is defined as hypertension (systolic blood pressure ≥ 140
mmHg and/or diastolic blood pressure ≥ 90 mmHg after 20 weeks’ gestation,
measured twice in a previously normotensive woman) with new-onset
proteinuria at or beyond 20 weeks’ gestation.
cHELLP syndrome is defined as a platelet count less than 100 * 109/L and
aspartate aminotransferase of 70 U/L or greater and lactate dehydrogenase of
600 U/L or greater.
dIntra uterine growth restriction is defined as birth weight < 10th percentile
for gestational age.
ePlacental abruption (also known as abruptio placentae) is a complication of
pregnancy, wherein the placental lining has separated from the uterus of the
mother. Diagnosis according to clinical criteria (vaginal bleeding and uterine
tenderness in combination with fetal distress necessitating prompt delivery)
and examination of the placenta.
fPremature birth is defined as birth < 37 weeks’ gestation.
gMajor physical anomalies are defined as physical anomalies that have
cosmetic or functional significance.
hDeep vein thrombosis and pulmonary embolism are defined as abnormal
compression ultrasound or an intraluminal filling defect on venography (deep
vein thrombosis), or an intraluminal filling defect on spiral computed
tomography (CT) scan, cut-off of vessels more than 2.5 mm in diameter on
pulmonary angiogram or a perfusion defect of at least 75% of a segment with
a local normal ventilation result (high-probability) on ventilation/perfusion
lung scan (pulmonary embolism).
Criteria for bleeding are listed in Table 2.
ACCP, American College of Chest Physicians; LMWH, low-molecular-weight
heparin.
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intervention group inject LMWH once daily in addition
to standard pregnancy surveillance. Women in the con-
trol group receive standard pregnancy surveillance. Since
blinding of patients or investigators is deemed unfeasible
due to the nature of the intervention, an adjudication
committee, whose members are blinded for the interven-
tion, will assess primary and secondary outcome mea-
sures. End of follow-up is at 6 weeks after delivery or
miscarriage. Members of the blinded adjudication com-
mittee will be Prof. Dr. MH Prins, MD, epidemiologist
and Dr. WM Ankum, gynecologist.
The study intervention is LMWH at a dose that has
been widely used in pregnant patients, and that is compar-
able with prophylaxis of VTE after orthopedic surgery,
and is administered once daily, subcutaneously. The ra-
tionale for this dose is that it is high enough to produce
an effect (that is higher than the standard prophylaxis
dose of 20 mg), but not as high as the therapeutic VTE
dose, to minimize the bleeding risks. Furthermore, there is
great experience with this specific anticoagulant in obstet-
rics and previous studies and its safety profile is well
established. Women are instructed to inject themselves
daily in either the upper leg or abdomen.
The recommended intervention is:
 Clexane (enoxaparin, Sanofi-Aventis Netherlands
B.V., Kampenringweg 45 E, 2803 PE GOUDA, the
Netherlands) 40 mg LMWH, administered subcuta-
neously, 100mg/mL, 0.4mL syringe.
If the recommended intervention is unavailable (e.g.,,
for practical or financial reasons in different countries),
another type of LMWH in a dosage equivalent to enoxa-
parin 40 mg can be chosen from the list below:
 Fraxiparin (nadroparin, GlaxoSmithKline bv, 980
Great West Road, Brentford, Middlesex, United
Kingdom) 3,800 IU anti-Xa LMWH, 9,500 IU anti-
Xa/mL, 0.4mL syringe.
 Fragmin (dalteparin, Pfizer bv, 235 East 42nd Street,
NY, NY 10017, USA) 5,000 IU LMWH, 25,000 IU/
mL, 0.2mL syringe.
 Innohep (tinzaparin, Leo Pharma bv, Industriparken
55, DK-2750 Ballerup, Denmark) 4,500 IU LMWH,
4,500 IU syringe.
Doses will not be adjusted to body weight. In case none
of the LMWH preparations is available, any other locally
available LMWH, in a corresponding dosage and ap-
proved by the Trial Management Team (headed by princi-
pal investigators S Middeldorp and M Goddijn) is allowed.
Apart from the assigned study medication, women are
strongly discouraged from using antithrombotic or other
medications that affect hemostasis, including NSAIDs.
Table 2 Criteria for major, clinically relevant non-major and minor bleeding
Major bleeding • Associated with a fall in hemoglobin of 2 g/dL or more
• Leading to a transfusion of two or more units of packed red blood cells or whole blood
• Occurring in a critical site: intracranial, intra-spinal, intra-ocular, pericardial, intra-articular,
intramuscular with compartment syndrome, retro-peritoneal
• Contributing to death
Clinically relevant non-major bleeding • Any bleeding compromising hemodynamics
• Any bleeding leading to hospitalization
• Subcutaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause
• Intramuscular hematoma documented by ultrasonography
• Epistaxis lasting > 5 minutes, repetitive (defined as two or more episodes of bleeding more
extensive than spots on a handkerchief within 24 hours), or leading to an intervention
(e.g.,,, packing or electrocoagulation)
• Gingival bleeding occurring spontaneously (not related to eating, flossing or tooth brushing)
or lasting > 5 minutes
• Macroscopic spontaneous hematuria or hematuria that lasted > 24 hours after instrumentation
(e.g., catheter placement or surgery) of the urogenital tract
• Macroscopic gastrointestinal hemorrhage, including at least one episode of melena or
hematemesis, with positive results on a fecal occult-blood test
• Hemoptysis, if more than a few speckles in the sputum and not occurring within the context of
pulmonary embolism
• Any other bleeding type considered to have clinical consequences for a patient such as medical
intervention, the need for unscheduled contact (visit or telephone call) with a physician, or
temporary cessation of a study drug or associated with pain or impairment of daily life activities
Minor bleeding All other overt bleeding episodes not meeting the criteria for major or clinically relevant
bleeding or post-partum bleeding.
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Aspirin at a low dose (≤100 mg daily) to lower the risk
for recurrent preeclampsia (at the discretion of the
treating physician) is allowed, and is recorded. All
women are encouraged to take folic acid 400 μg daily,
starting before conception and continuing until 8 weeks
after conception, as routine prophylaxis for neural tube
defects.
The study will be conducted in several international
centers, both tertiary and non-tertiary. A list of participat-
ing centers and countries is available from the sponsor.
Ethics
The study was approved by the Institutional Review Board
(IRB) of the Academic Medical Center (IRB registration
number METC_2012_173) and is conducted according to
the principles of the World Medical Association (WMA)
Declaration of Helsinki - Ethical Principles for Medical
Research Involving Human Subjects Version Seoul, South
Korea, October 2008, with Note of Clarification on
Paragraph 29 added by the WMA General Assembly,
Washington 2002; Note of Clarification on Paragraph
30 added by the WMA General Assembly, Tokyo 2004
and in accordance with the Dutch Medical Research In-
volving Human Subjects Act (WMO) and other guide-
lines, regulations and Acts.
Recruitment in individual centers will be commenced
after local approval is obtained.
Study procedures
Women, aged 18 to 42 at randomization, with a history
of 2 or more miscarriages and/or intra-uterine fetal
deaths with confirmed inherited thrombophilia, who are
actively trying to conceive or are less than 7 weeks preg-
nant are recruited for the study. They are informed of
the study by their treating physician and receive written
study information. Women are instructed to perform a
urine pregnancy test as soon as their menstrual periods
are delayed or a pregnancy is suspected. Furthermore,
they are contacted by telephone at 3-month intervals
until they are pregnant. Once a urine test confirms preg-
nancy and all in- and exclusion criteria are met (Table 3),
including signing of informed consent (see Additional
file 1), they are randomized to either the intervention
arm or the standard pregnancy surveillance arm of the
study. Informed consent will be obtained by Good-
Clinical-Practice-trained study personnel with use of the
review-board approved consent form. Women will only
be randomized in the study after informed consent is
obtained.
Randomization is performed centrally, online via a se-
cure Internet facility in a 1:1 ratio by the TENALEA
Clinical Trial Data Management System using randomly
permuted blocks with maximum block size of 6 within
strata formed by maternal age (<36 or ≥ 36 years), num-
ber of miscarriages (2 or ≥ 3) and center type (tertiary or
non-tertiary). Both the including physician and patient
are concealed for allocation.
Women who are randomized to intervention arm start
with LMWH immediately. They undergo a blood test
twice (2.7 mL at baseline and 2.7 mL after 7 to 10 days)
to check for heparin-induced thrombocytopenia and are
instructed to discontinue LMWH when they experience
the first signs of labor. In case of a planned delivery or
cesarean section, LMWH should be discontinued ac-
cording to local policy, but at least 12 hours prior to
neuraxial anesthesia or cesarean section. Randomized
women will be contacted at 12 and 24 weeks’ gestation
and 6 weeks post-partum to collect outcome data and
Figure 1 Flowchart of the ALIFE2 study.
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data on adverse events. No additional study visits are
planned.
Women in both study arms will receive standard preg-
nancy surveillance. Data from routine obstetric visits is
recorded in a case record form (CRF) for analysis, in-
cluding medical history and family history. Additionally,
maternal bleeding episodes, thrombotic signs, and pos-
sible reactions to study medication are monitored.
Women are instructed to contact the study center im-
mediately when bleeding episodes occur or when devel-
oping (possibly heparin- induced) thrombocytopenia.
In case of a (serious) adverse event, emergency medi-
cation is administered by treating physicians according
to local policy; e.g., in case of a major bleeding a patient
may receive blood transfusions and/or antidote (e.g.,
protamine sulfate).
In case of serious type IV delayed hypersensitivity skin
reactions to LMWH, an alternative form of LMWH can
be prescribed. In case of type I allergy, LMWH must be
discontinued.
The CRF can be downloaded from the study website
www.ALIFE2study.org. Data handling will be coded,
with the patient code only available to the local investi-
gator and the research nurse working in the local center.
Data recorded in the CRFs will be collected in an elec-
tronic CRF, accessible via the study website.
Women withdrawn from treatment will be asked to
continue follow-up until the end of study (that is 6
weeks after delivery or miscarriage).
Important protocol modifications will be communi-
cated to all relevant parties (e.g.,,. investigators, trial
nurses, review boards, trial participants, trial registries
and journals) if indicated.
The study sponsor is the Academic Medical Center,
University of Amsterdam, Meibergdreef 9, 1105 AZ,
Amsterdam, the Netherlands. The currently approved
study protocol is version 4.0, dated 18 August 2014. The
full study protocol can be accessed via the study website
(www.ALIFE2study.org).
Recruitment is currently taking place in the Netherlands
and Belgium and is planned for the United Kingdom, the
United States of America, Canada, and Australia and is
open to more countries.
Statistical analyses
Baseline data and outcome data will be summarized sep-
arately. For continuous variables, we will examine the
distribution of the observations and, if normally distrib-
uted, we will then summarize them as means with stand-
ard deviations (SDs). If they are not normally distributed,
then medians and inter-quartile ranges (IRQs) will be re-
ported. For dichotomous data, we will provide proportions
(or percentages).
Differences in dichotomous outcomes between the two
treatment arms will be analyzed using the chi-square test.
For continuous outcomes we will use the independent
t-test if the observations in each study arm are nor-
mally distributed, and if non-normally distributed, the
Table 3 Inclusion and exclusion criteria
Inclusion criteria • Women with recurrent miscarriage and/or intra-uterine fetal deaths (that is ≥ two miscarriages of intra-uterine
fetal deaths, irrespective of gestational age)
• Confirmed inherited thrombophiliaa
◦ factor V Leiden mutation
◦ prothrombin gene mutation (G20210A)
◦ protein S deficiency
◦ protein C deficiency
◦ antithrombin deficiency
• Pregnancy confirmed by urine pregnancy test
• Age 18 to 42 years at randomization
• Willing and able to give informed consent
Exclusion criteria • Duration of current pregnancy ≥ 7 weeks, based on first day of last menstruation
• Indication for anticoagulant treatment during pregnancy (e.g., prosthetic heart valves, a history of venous
thromboembolism or antiphospholipid syndrome)
• Contraindications to LMWH (previous heparin-induced thrombocytopenia, active bleeding or renal insufficiency
with creatinine clearance of < 30 ml/minute)
• Known allergy to at least three different LMWH preparations
• Previous inclusion in the ALIFE2 study (for another pregnancy)
aProtein S, protein C and antithrombin deficiencies need to be confirmed by two tests, performed on two separate occasions and not during anticoagulant
therapy. Protein S tests should not be performed during pregnancy or in the 6-week post-partum period since spuriously low levels may then be observed.
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Mann-Whitney U-test will be employed. For all out-
come measures, we will calculate 95% CIs around point
estimates.
The exploration of differential or subgroup effects of
LMWH will be assessed in a priori-defined prognostic
groups: age (continuous and dichotomized), number of
previous miscarriages (two, or three or more), previous
live birth (yes/no), type of inherited thrombophilia (fac-
tor V Leiden mutation, Prothrombin gene G20210A mu-
tation PTM, antithrombin deficiency, protein C
deficiency and protein S deficiency).
For issues such as loss to follow-up, missing data, and
protocol violations, we will attempt sensitivity (‘worst-
case and best-case scenarios’) analyses to explore the ef-
fect on the study findings. As a secondary analysis, we
will adjust for missing data using imputation techniques
to explore the effects of such imputations on the study
findings.
Efficacy analyses will be based on the intention-to-
treat (ITT) principle. A P-value of less than 0.05 will be
considered statistically significant. All statistical analyses
will be performed using the SPSS package (SPSS Inc.,
Chicago, IL, USA).
Sample size calculation
In the previous ALIFE study [8], the occurrence of live
birth in the subgroup of women who had an inherited
thrombophilia and became pregnant was 60% in those
randomized to placebo. Based on this information, a
conservative sample size assuming a live birth of 55% in
the control group is calculated. In order to detect an
absolute risk difference of 15%, with a power of 80%
and a 2-sided confidence level of 95%, the sample size
required for the study is n = 332, with 166 women in
each arm. Taking a potential loss to follow-up and ex-
clusion from the study (due to ectopic pregnancy for
example) into consideration, we aim to recruit 20%
more women (n = 399).
The absolute risk difference of 15% was defined fol-
lowing consultations amongst health care providers and
patients. Since we acknowledge that from a patient’s per-
spective, a 10% absolute risk difference is still clinically
relevant, we also plan to perform a conditional interim
analysis to adjust the sample size. When approximately
95% of inclusion is reached, the adjudication committee
will analyze efficacy outcome, blinded for allocation. If
the estimated difference in live birth between the 2
groups is below 10% or above 15%, the study will con-
tinue as planned and will be completed with 399 en-
rolled women. However, if the estimated difference in
live birth is between 10% and 15%, we will explore (fi-
nancial) means and evaluate if continued recruitment
until a total sample size of 776 women is feasible so that
the study is sufficiently powered to assess this effect. For
this interim analysis we will use a total 2-sided signifi-
cance test with the O’Brien-Fleming alpha spending
function and a type I error rate of 5%. Evaluable women
are all women included (randomized) in the study.
In the Netherlands we aim to recruit 200 women;
therefore, approximately 200 women will be recruited in
other countries. This will be pragmatically adjusted de-
pending on recruitment status.
Data Monitoring Committee (DMC)
A Data Monitoring Committee is installed for the
ALIFE2 study. A DMC charter is supplementary to this
protocol and available from the sponsor. Monitoring will
be performed in collaboration with the Academic Med-
ical Center Clinical Research Unit (CRU). A monitoring
plan was drafted accordingly and is available with the
sponsor. Members of the DMC are Prof. Dr. HR Büller,
AMC, Amsterdam (chair); Dr. WM Ankum, gynecologist,
AMC, Amsterdam and Prof. Dr. M Prins, statistician,
Maastricht University Medical Center, Maastricht.
The final trial dataset will be accessible by the lead in-
vestigator and statistical analysis team at the Academic
Medical Center CRU. No contractual arrangements are
in place that limit such access for investigators
Adverse events
LMWH is registered and recommended for a wide var-
iety of indications. Also to pregnant women, LMWH is
prescribed for several indications and in higher dosages
than is used in the ALIFE2 study. Therefore, the spectrum
of adverse events is well documented in regular patients
as well as in pregnant women. For this reason, not all un-
desirable experiences occurring to women are recorded,
but only adverse events that are suspected to be related to
study medication. These adverse events include: clinically
relevant bleeding (major or clinically relevant non-major
bleeding) and any bleeding (hematoma, epistaxis, bleeding
of gums, vaginal blood loss, hematuria or any other form
of bleeding), heparin-induced thrombocytopenia, skin re-
action to injection (e.g.,, itching, swelling) and (type 1) al-
lergic reactions. When hematomas are related to
venipuncture, only hematomas larger than 10 × 10 cm are
reported.
For all events recorded, the nature and severity will be
assessed. A serious adverse event (SAE) is any untoward
medical occurrence or effect that at any dose that:
 results in death
 is life-threatening (at the time of the event)
 requires hospitalization or prolongation of existing
inpatient hospitalization
 results in persistent or significant disability or
incapacity
 is a congenital anomaly or birth defect
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 is a new event of the study likely to affect the safety
of the subjects, such as an unexpected outcome of
an adverse reaction, lack of efficacy of an
investigational medicinal product used for the
treatment of a life-threatening disease, major safety
finding from a newly completed animal study, and
so on
SAEs that result in death or are life-threatening should
be reported immediately. The reporting will occur not
later than 7 days after the responsible investigator has
first knowledge of the adverse reaction. This is for a pre-
liminary report with another 8 days for completion of
the report. The study efficacy outcome ‘bleeding’ will not
be reported as SAE. A standard practice of hospitalization
(e.g., for delivery) will not be considered as a prolonged
hospitalization and should not be reported as an SAE.
However, if this transfer is part of treatment of a med-
ical complication, it should be considered prolonged
hospitalization and the event should be reported as a
SAE. Clinically anticipated events, such as bleeding, are
exempted from the expedited reporting to regulatory
authorities of suspected adverse reactions that are both
serious and unexpected. These clinically anticipated
events are periodically reviewed by the DMC in an un-
blinded manner to ensure prompt identification of any
clinically concerning safety issues.
Public disclosure and publication policy
A writing committee chaired by the principal investiga-
tors will be put in place as the trial progresses. The
composition of the committee will reflect the contribu-
tion of investigators to various aspects of the trial, in-
cluding but not solely the conception and design,
acquiring of funding, country coordination and recruit-
ment of patients. This committee will write the study
report, and the report will include list of centers and in-
vestigators that contributed patients to the study. There
are no publications restrictions by the sponsor of the
study.
Furthermore, trial results will be posted on the study
website and communicated through patients via patient
organization websites.
Compensation for injury
The sponsor/investigator in the Netherlands has a liabil-
ity insurance that is in accordance with article 7, subsec-
tion 6 of the WMO.
The sponsor (also) has an insurance which is in ac-
cordance with the legal requirements in the Netherlands
(Article 7 WMO and the Measure regarding Compul-
sory Insurance for Clinical Research in Humans of 23
June 2003). This insurance provides cover for damage to
research subjects through injury or death caused by the
study:
1. €450,000 - for death or injury for each subject who
participates in the research;
2. €3,500,000 - for death or injury for all subjects who
participate in the research;
3. €5,000,000 - for the total damage incurred by the
organization for all damage disclosed by scientific re-
search for the sponsor as ‘verrichter’ in the meaning
of said Act in each year of insurance coverage.
The insurance applies to the damage that becomes ap-
parent during the study or within 4 years after the end
of the study and is only applicable to patients included
in the Netherlands.
Discussion
The choice for the intervention with LMWH in the
ALIFE2 study was based on the following considerations.
In the previous ALIFE study, LMWH was administered
in combination with aspirin and compared with aspirin
alone and to no-intervention (placebo for aspirin) in
women with recurrent miscarriage of unknown cause
[8]. Since there are no solid data supporting an effect of
aspirin in women with recurrent miscarriage, with or
without inherited thrombophilia, we chose to use
LMWH as intervention, without aspirin as additional
intervention in the ALIFE2 study, to exclude a possible
deleterious effect of aspirin.
The dose of LMWH is higher than low-prophylactic
dosages, in order not to miss a beneficial effect of
LMWH on live birth. However, because results from the
Live-Enox study showed no difference in live birth in
women randomized to 40 mg enoxaparin or 80 mg
enoxaparin, we chose to use the dosage of 40 mg enoxa-
parin to reduce the bleeding risk [23].
A timely execution of the trial is impeded because of
two reasons. Firstly, the assumed efficacy of LMWH
triggers physicians to give LMWH the benefit of the
doubt. They offer the treatment despite a lack of its evi-
dence; especially in poignant cases as for example
women with a history of multiple miscarriages. Eligible
women will thus be reluctant to be randomized, facing a
50% chance of no-treatment, when they can also ap-
proach physicians who are willing to prescribe them
LMWH outside the context of the study. This hurdle
can be overcome, provided both physicians and patients
are well informed. Physicians who are aware of the lack
of evidence for LMWH and the non-negligible bleeding
risk associated with this treatment clearly understand
the need for the study. They are more willing to contrib-
ute to recruitment and comply with guidelines advising
not to treat in absence of evidence for treatment. A
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second reason for delay, potentially specific to the Dutch
situation, is that eligible women for the study remain un-
identified because screening for inherited thrombophilia
is not standard practice. A complete thrombophilia
screen is expensive and as currently no proven effective
treatment for women with recurrent miscarriage and
inherited thrombophilia is available, testing for inherited
thrombophilia (solely for the indication or recurrent
miscarriage) is not always performed. Nonetheless, many
women have already been tested for thrombophilia be-
cause of other reasons such as a positive family history
of VTE. Moreover, as screening for inherited thrombo-
philia may provide an explanation for recurrent miscar-
riage, some physicians perform screening not to identify
a treatable condition but to provide couples with this ex-
planation. In this way, even physicians who do not in-
corporate thrombophilia screening in their standard
practice can contribute to recruitment, identifying these
women.
Trial status
The study commenced recruiting in January 2013 in the
Netherlands, with at present 11 participating centers and
2 additional centers for which ethics approval is ex-
pected shortly. Participation of non-Dutch centers was
initiated by the University Hospital of Brussels in
Belgium, which is expected to be followed closely by
centers in the United Kingdom, the United States,
Canada and Sweden.
At the time of writing 23 women have been randomized
in the study. An initially slow recruitment is currently
catching up to a rate of approximately 2 inclusions per
month in the Netherlands, expected to increase to 4 per
month with continuing expansion of the number of par-
ticipating centers and increasing awareness of the study.
Confirmed participation of centers abroad and especially
dedicated recurrent miscarriage clinics in the United
Kingdom is expected to further increase this rate to an
eventual inclusion rate of 14 women per month.
As with most investigator-initiated multi-center trials,
several hurdles, such as an administrative workload,
(international) legislation and applications for approval
in participating centers, and initial slow recruitment, had
to be overcome to get the trial running. However, with
these hurdles overcome, the trial now seems to have
reached a new phase, with a steadily increasing recruit-
ment rate, towards completion of the trial.
Endnote
The study website can be accessed via www.ALIFE2s-
tudy.org. The study is still open for additional participat-
ing centers. If you consider participation in the ALIFE2
study, please contact the study authors.
Additional file
Additional file 1: Patient information and informed consent form.
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